DeFinium Therapeutics Inc (DFTX)

$46.14 0.00 (N/A)
Market Cap 4.60B
Revenue (ttm) 0.00
Net Income (ttm) -183.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 2,547,200
Avg Vol 3,156,492
Day's Range N/A - N/A
Shares Out 99.70M
Stochastic %K 62%
Beta 2.23
Analysts Strong Sell
Price Target $60.00

Company Profile

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Me...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 220 6633
Address:
One World Trade Center, Suite 8500, New York, United States
MichaelHoffman435
MichaelHoffman435 Aug. 9 at 2:46 PM
$DFTX $WULF $MRNA $SNOW $BA DFTX remains highly speculative, TeraWulf benefits from Bitcoin mining and AI data-center demand, Moderna continues expanding its mRNA pipeline, Snowflake benefits from cloud-data and AI workloads, and Boeing remains focused on production recovery and aerospace execution. I'm watching funding, AI infrastructure, clinical progress, and aircraft deliveries.
0 · Reply
ErikCanary202
ErikCanary202 Aug. 9 at 11:12 AM
$DFTX $WULF $MRNA $SNOW $BA DFTX remains highly speculative, TeraWulf benefits from Bitcoin mining and AI data-center demand, Moderna continues expanding its mRNA pipeline, Snowflake benefits from cloud-data and AI workloads, and Boeing remains focused on production recovery and aerospace execution. I'm watching funding, AI infrastructure, clinical progress, and aircraft deliveries.
0 · Reply
Rocketzz
Rocketzz Aug. 8 at 11:49 PM
$DFTX
1 · Reply
Canadian10
Canadian10 Aug. 8 at 10:37 PM
$DFTX
0 · Reply
Jack37615
Jack37615 Aug. 8 at 9:33 PM
$DFTX I’m loving our odds of the trial going our way. The Phase 2B drives conviction through the roof. Setting another buy order for 1000 shares on Monday. If deemed successful, I see it going north of 60, potentially 70 for a brief moment. The asymmetrical setup is awesome.
2 · Reply
FBP
FBP Aug. 8 at 8:58 PM
$CMPS if we dip to 11s again I might have go bigly big. This is still early stage of alt ptsd depression etc drugs $DFTX is up there too
0 · Reply
zhang7946
zhang7946 Aug. 8 at 7:22 PM
$DFTX
0 · Reply
Stock_Tournaments
Stock_Tournaments Aug. 8 at 7:19 PM
$DFTX Play-by-Play: positive Phase 3 depression data already fuels huge biotech run → company confirms next major Phase 3 anxiety readout is coming week of Aug. 10 → traders hold positions ahead of binary catalyst → DFTX finishes flat.
0 · Reply
Rocketzz
Rocketzz Aug. 8 at 7:15 PM
$DFTX
1 · Reply
Clontz
Clontz Aug. 8 at 7:06 PM
$DFTX something big is coming.
1 · Reply
Latest News on DFTX
Definium Therapeutics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 2 days ago

Definium Therapeutics Earnings Call Transcript: Q2 2026

Definium Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 2 days ago

Definium Therapeutics Earnings release: Q2 2026

Definium Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 2 days ago

Definium Therapeutics Quarterly report: Q2 2026

Definium Therapeutics reports Q2 EPS ($1.44), consensus (53c)

2026-08-06T20:17:59.000Z - 2 days ago

Definium Therapeutics reports Q2 EPS ($1.44), consensus (53c)

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Aug 6, 2026, 4:01 PM EDT - 2 days ago

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Definium Therapeutics Announces New Employee Inducement Grants

Aug 3, 2026, 4:01 PM EDT - 5 days ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Jul 30, 2026, 4:01 PM EDT - 9 days ago

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Definium Therapeutics initiated with an Overweight at Wells Fargo

2026-07-27T09:25:21.000Z - 13 days ago

Definium Therapeutics initiated with an Overweight at Wells Fargo

Definium Therapeutics price target raised to $73 from $48 at Piper Sandler

2026-07-24T10:55:21.000Z - 16 days ago

Definium Therapeutics price target raised to $73 from $48 at Piper Sandler

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

Jul 16, 2026, 7:00 AM EDT - 24 days ago

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

Definium Therapeutics announces results from healthcare claims study in GAD

2026-07-14T11:11:22.000Z - 26 days ago

Definium Therapeutics announces results from healthcare claims study in GAD

New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)

Jul 14, 2026, 7:00 AM EDT - 26 days ago

New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)

Definium Therapeutics price target raised to $60 from $30 at Stifel

2026-07-08T11:11:17.000Z - 4 weeks ago

Definium Therapeutics price target raised to $60 from $30 at Stifel

Definium Therapeutics price target lowered to $58 from $60 at Canaccord

2026-06-30T11:05:29.000Z - 5 weeks ago

Definium Therapeutics price target lowered to $58 from $60 at Canaccord

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

Jun 26, 2026, 9:30 AM EDT - 6 weeks ago

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

CMPS

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 25, 2026, 4:15 PM EDT - 6 weeks ago

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Biotech ETF Index Surges 10% After Rebalance

Jun 25, 2026, 11:31 AM EDT - 6 weeks ago

Biotech ETF Index Surges 10% After Rebalance

ALKS APGE DYN KLRA KYMR MANE MIRM

Definium Therapeutics rises 21.8%

2026-06-24T16:05:36.000Z - 6 weeks ago

Definium Therapeutics rises 21.8%

Definium Therapeutics Stock (DFTX) Soars on a Public Offering Pricing After Strong Trial Results

2026-06-24T15:25:15.000Z - 6 weeks ago

Definium Therapeutics Stock (DFTX) Soars on a Public Offering Pricing After Strong Trial Results

BAC JEF JPM

Definium Therapeutics rises 17.7%

2026-06-24T14:05:51.000Z - 6 weeks ago

Definium Therapeutics rises 17.7%

Definium Therapeutics 20.6M share Secondary priced at $34.00

2026-06-24T10:20:19.000Z - 6 weeks ago

Definium Therapeutics 20.6M share Secondary priced at $34.00

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

Jun 23, 2026, 9:57 PM EDT - 6 weeks ago

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

Definium Therapeutics, Inc. Announces Proposed Public Offering

Jun 22, 2026, 4:01 PM EDT - 6 weeks ago

Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics Transcript: Study result

Jun 22, 2026, 8:00 AM EDT - 6 weeks ago

Definium Therapeutics Transcript: Study result

Definium Therapeutics Press release: Study result

Jun 22, 2026, 8:00 AM EDT - 6 weeks ago

Definium Therapeutics Press release: Study result

Definium Therapeutics Slides: Study result

Jun 22, 2026, 8:00 AM EDT - 6 weeks ago

Definium Therapeutics Slides: Study result

Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder

Jun 22, 2026, 7:00 AM EDT - 6 weeks ago

Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder

Definium Therapeutics Slides: Corporate presentation

Jun 22, 2026, 7:00 AM EDT - 6 weeks ago

Definium Therapeutics Slides: Corporate presentation

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Jun 21, 2026, 5:00 PM EDT - 6 weeks ago

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Definium Therapeutics Transcript: AGM 2026

Jun 11, 2026, 10:00 AM EDT - 2 months ago

Definium Therapeutics Transcript: AGM 2026

Definium Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 3:10 PM EDT - 2 months ago

Definium Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

May 21, 2026, 7:00 AM EDT - 2 months ago

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Definium Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 8:00 AM EDT - 2 months ago

Definium Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

May 12, 2026, 7:00 AM EDT - 3 months ago

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

Definium Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Definium Therapeutics Earnings Call Transcript: Q1 2026

Definium Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Definium Therapeutics Earnings release: Q1 2026

Definium Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Definium Therapeutics Quarterly report: Q1 2026

Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 7, 2026, 4:01 PM EDT - 3 months ago

Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Definium Therapeutics Slides: Corporate presentation

May 7, 2026, 4:00 PM EDT - 3 months ago

Definium Therapeutics Slides: Corporate presentation

Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 30, 2026, 4:01 PM EDT - 3 months ago

Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Definium Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Definium Therapeutics Proxy statement: Proxy filing

Definium Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Definium Therapeutics Proxy statement: Proxy filing

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

Apr 22, 2026, 4:15 PM EDT - 3 months ago

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

Definium Therapeutics Transcript: Investor Day 2026

Apr 22, 2026, 10:00 AM EDT - 3 months ago

Definium Therapeutics Transcript: Investor Day 2026

Definium Therapeutics Slides: FY 2026

Apr 22, 2026, 10:00 AM EDT - 3 months ago

Definium Therapeutics Slides: FY 2026

How Trump's psychedelics executive order could unlock stalled cannabis reform

Apr 20, 2026, 2:05 PM EDT - 3 months ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS HELP GHRS

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

Apr 20, 2026, 10:45 AM EDT - 3 months ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

ATAI CMPS GHRS

Psychedelic stocks rally with Trump's support

Apr 20, 2026, 8:26 AM EDT - 3 months ago

Psychedelic stocks rally with Trump's support

ATAI CMPS GHRS

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

Apr 20, 2026, 8:18 AM EDT - 3 months ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

ATAI CMPS GHRS

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

Apr 20, 2026, 6:43 AM EDT - 3 months ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS ENVB GHRS HELP

Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

Apr 18, 2026, 7:38 PM EDT - 4 months ago

Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

Definium Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 3:00 PM EDT - 4 months ago

Definium Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Apr 9, 2026, 7:00 AM EDT - 4 months ago

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

Mar 31, 2026, 7:00 AM EDT - 4 months ago

New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Mar 26, 2026, 7:00 AM EDT - 4 months ago

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Definium Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 3:30 PM EDT - 5 months ago

Definium Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Definium Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 1:00 PM EDT - 5 months ago

Definium Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Definium Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 5 months ago

Definium Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Definium Therapeutics Slides: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 5 months ago

Definium Therapeutics Slides: TD Cowen 46th Annual Health Care Conference

Definium Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 5 months ago

Definium Therapeutics Earnings Call Transcript: Q4 2025

Definium Therapeutics Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 5 months ago

Definium Therapeutics Annual report: Q4 2025

Definium Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 5 months ago

Definium Therapeutics Earnings release: Q4 2025

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Feb 26, 2026, 4:01 PM EST - 5 months ago

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Definium Therapeutics Slides: Corporate presentation

Feb 26, 2026, 4:00 PM EST - 5 months ago

Definium Therapeutics Slides: Corporate presentation

Definium Therapeutics to Participate at Upcoming Investor Conferences

Feb 24, 2026, 7:01 AM EST - 5 months ago

Definium Therapeutics to Participate at Upcoming Investor Conferences

Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Feb 19, 2026, 4:01 PM EST - 6 months ago

Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Definium Therapeutics Appoints Roger Adsett to Board of Directors

Jan 29, 2026, 7:00 AM EST - 6 months ago

Definium Therapeutics Appoints Roger Adsett to Board of Directors

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Jan 20, 2026, 7:00 AM EST - 7 months ago

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Definium Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 5:15 PM EST - 7 months ago

Definium Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Jan 13, 2026, 7:00 AM EST - 7 months ago

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Definium Therapeutics Slides: Corporate presentation

Jan 12, 2026, 2:45 PM EST - 7 months ago

Definium Therapeutics Slides: Corporate presentation

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

Jan 12, 2026, 7:00 AM EST - 7 months ago

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:01 AM EST - 8 months ago

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

MindMed Announces New Employee Inducement Grant

Dec 15, 2025, 4:01 PM EST - 8 months ago

MindMed Announces New Employee Inducement Grant

Definium Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 3:00 PM EST - 8 months ago

Definium Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Definium Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 12:30 PM EST - 8 months ago

Definium Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

MindMed Announces New Employee Inducement Grants

Dec 1, 2025, 4:01 PM EST - 8 months ago

MindMed Announces New Employee Inducement Grants

Definium Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 7:00 AM EST - 9 months ago

Definium Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Definium Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 1:20 PM EST - 9 months ago

Definium Therapeutics Transcript: Stifel 2025 Healthcare Conference

Definium Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 9 months ago

Definium Therapeutics Slides: Corporate Presentation

Definium Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Definium Therapeutics Earnings Call Transcript: Q3 2025

Definium Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Definium Therapeutics Quarterly report: Q3 2025

Definium Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Definium Therapeutics Earnings release: Q3 2025

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 6, 2025, 4:01 PM EST - 9 months ago

MindMed Reports Q3 2025 Financial Results and Business Updates

Definium Therapeutics Slides: Corporate Presentation

Nov 6, 2025, 7:00 AM EST - 9 months ago

Definium Therapeutics Slides: Corporate Presentation

MindMed to Participate in Upcoming Investor Conferences

Nov 5, 2025, 7:01 AM EST - 9 months ago

MindMed to Participate in Upcoming Investor Conferences

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Nov 3, 2025, 7:01 AM EST - 9 months ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 30, 2025, 4:01 PM EDT - 10 months ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 10:14 PM EDT - 10 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 10 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 19, 2025, 7:00 AM EDT - 11 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Definium Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 18, 2025, 1:00 PM EDT - 11 months ago

Definium Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Definium Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 3:30 PM EDT - 11 months ago

Definium Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 1 year ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

MindMed to Participate in September Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 1 year ago

MindMed to Participate in September Investor Conferences

Definium Therapeutics Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

Definium Therapeutics Earnings Call Transcript: Q2 2025

Definium Therapeutics Quarterly report: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

Definium Therapeutics Quarterly report: Q2 2025

Definium Therapeutics Earnings release: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

Definium Therapeutics Earnings release: Q2 2025

Definium Therapeutics Slides: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

Definium Therapeutics Slides: Q2 2025

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 31, 2025, 4:01 PM EDT - 1 year ago

MindMed Reports Q2 2025 Financial Results and Business Updates

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jul 24, 2025, 7:00 AM EDT - 1 year ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Definium Therapeutics Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Definium Therapeutics Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Definium Therapeutics Transcript: AGM 2025

Jun 12, 2025, 10:00 AM EDT - 1 year ago

Definium Therapeutics Transcript: AGM 2025

Definium Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Definium Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

MindMed to Participate in June Investor Conferences

May 28, 2025, 7:00 AM EDT - 1 year ago

MindMed to Participate in June Investor Conferences

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025, 7:00 AM EDT - 1 year ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

Definium Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 21, 2025, 2:05 PM EDT - 1 year ago

Definium Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 1 year ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

MichaelHoffman435
MichaelHoffman435 Aug. 9 at 2:46 PM
$DFTX $WULF $MRNA $SNOW $BA DFTX remains highly speculative, TeraWulf benefits from Bitcoin mining and AI data-center demand, Moderna continues expanding its mRNA pipeline, Snowflake benefits from cloud-data and AI workloads, and Boeing remains focused on production recovery and aerospace execution. I'm watching funding, AI infrastructure, clinical progress, and aircraft deliveries.
0 · Reply
ErikCanary202
ErikCanary202 Aug. 9 at 11:12 AM
$DFTX $WULF $MRNA $SNOW $BA DFTX remains highly speculative, TeraWulf benefits from Bitcoin mining and AI data-center demand, Moderna continues expanding its mRNA pipeline, Snowflake benefits from cloud-data and AI workloads, and Boeing remains focused on production recovery and aerospace execution. I'm watching funding, AI infrastructure, clinical progress, and aircraft deliveries.
0 · Reply
Rocketzz
Rocketzz Aug. 8 at 11:49 PM
$DFTX
1 · Reply
Canadian10
Canadian10 Aug. 8 at 10:37 PM
$DFTX
0 · Reply
Jack37615
Jack37615 Aug. 8 at 9:33 PM
$DFTX I’m loving our odds of the trial going our way. The Phase 2B drives conviction through the roof. Setting another buy order for 1000 shares on Monday. If deemed successful, I see it going north of 60, potentially 70 for a brief moment. The asymmetrical setup is awesome.
2 · Reply
FBP
FBP Aug. 8 at 8:58 PM
$CMPS if we dip to 11s again I might have go bigly big. This is still early stage of alt ptsd depression etc drugs $DFTX is up there too
0 · Reply
zhang7946
zhang7946 Aug. 8 at 7:22 PM
$DFTX
0 · Reply
Stock_Tournaments
Stock_Tournaments Aug. 8 at 7:19 PM
$DFTX Play-by-Play: positive Phase 3 depression data already fuels huge biotech run → company confirms next major Phase 3 anxiety readout is coming week of Aug. 10 → traders hold positions ahead of binary catalyst → DFTX finishes flat.
0 · Reply
Rocketzz
Rocketzz Aug. 8 at 7:15 PM
$DFTX
1 · Reply
Clontz
Clontz Aug. 8 at 7:06 PM
$DFTX something big is coming.
1 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Aug. 8 at 6:50 PM
$DFTX Trending 🔥
0 · Reply
janed102
janed102 Aug. 8 at 6:00 PM
$DFTX buying after data read, my luck it always goes down after data read and goes up before in anticipation
0 · Reply
buyoutorbust_
buyoutorbust_ Aug. 8 at 5:55 PM
$DFTX Cery cliche question but what’s your guys thoughts on the Pos that the trial meets its endpoint? Very tempted to set a heavier buy order Monday lol.
1 · Reply
MichaelNaussCMT
MichaelNaussCMT Aug. 8 at 2:44 PM
$DFTX 69
0 · Reply
BioRich
BioRich Aug. 8 at 2:22 PM
$DFTX locked and loaded. Had two orders go through by accident. Last time I did that it was with $TERN and that worked really well. Cheers!
0 · Reply
Monkey7779192
Monkey7779192 Aug. 8 at 12:14 PM
$DFTX PT if voyage result next week be great?
2 · Reply
Chukt22
Chukt22 Aug. 7 at 11:01 PM
$DFTX thankfully didn’t breakout. Got some covered calls that need to expire. Go crazy after 8/21
2 · Reply
Monkey7779192
Monkey7779192 Aug. 7 at 10:46 PM
$DFTX Readout on Monday right? Got some buy order.
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Aug. 7 at 9:28 PM
$DFTX I am the CMT so should be pro TA. But in this case all that matters is GAD results.
1 · Reply
MichaelNaussCMT
MichaelNaussCMT Aug. 7 at 9:27 PM
$DFTX
0 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Aug. 7 at 7:17 PM
$DFTX bounced off local support
0 · Reply
Sir_trades_a_lot69
Sir_trades_a_lot69 Aug. 7 at 4:39 PM
$DFTX No reason to worry here. $49.70 is the 52 week high. We bounced off 49.66 this morning to re-test. Then a typical sell-off by the momentum people who bought the stock yesterday for the first time and didn't research this company and their previous trial results. Expect DFTX to rally again late afternoon and easily break out to a new ATH next week when Phase 3 top line data is released. Buy the dip now, then trim a little next week when it hits 55 and again at 61. I bought more today at 45.
1 · Reply